Podcasts about vice chair

Support the Institute today: https://givenow.nova.edu/the-institute-for-neuro-immune-medicine-inim-2025   In this episode, Haylie Pomroy speaks with Dr. Theoharis Theoharides about the scientific foundations of brain fog. Together, they clarify its definition, physiological mechanisms, and how it presents across various illnesses and cognitive disorders. Dr. Theoharides further examines the relationship between brain fog and inflammation, explains how viral infections can contribute to the development of chronic illness, and discusses the role of microglia in neuroinflammation. He also reviews supplements that may help inhibit microglial activation, explains alpha-gal syndrome, and outlines relevant laboratory testing that can assist individuals experiencing brain fog in gaining clearer insight into their current health status. Dr. Theoharis Theoharides is a Professor, Vice Chair of Clinical Immunology, and Director at the Institute for Neuro-Immune Medicine-Clearwater, an Adjunct Professor of Immunology at Tufts School of Medicine, where he was a Professor of Pharmacology and Internal Medicine, and also the  Director of Molecular Immunopharmacology & Drug Discovery, and Clinical Pharmacologist at the Massachusetts Drug Formulary Commission (1983-2022). He received his BA, MS, MPhil, PhD, and MD degrees and the Winternitz Price in Pathology from Yale University and received a Certificate in Global Leadership from Tufts Fletcher School of Law and Diplomacy and a Fellowship at Harvard Kennedy  School of Government. He trained in internal medicine at New England Medical Center, which awarded him the Oliver Smith Award, "recognizing excellence, compassion, and service." Dr. Theoharides has 485 publications (46,491 citations; h-index 106), placing him in the world's top 2% of most cited authors, and he was rated the worldwide expert on mast cells by Expertscape. He was inducted into the Alpha Omega Alpha National Medical Honor Society, the Rare Diseases Hall of Fame, and the World Academy of Sciences. Website: https://www.drtheoharides.com LinkedIn: linkedin.com/in/theoharis-theoharides-ms-phd-md-faaaai-67123735 Instagram: https://www.instagram.com/dr.theoharides/   Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet.   Learn more about Haylie Pomroy's approach to wellness through her website: https://hayliepomroy.com   Instagram: https://www.instagram.com/hayliepomroy  Facebook: https://www.facebook.com/hayliepomroy  YouTube: https://www.youtube.com/@hayliepomroy/videos  LinkedIn: https://www.linkedin.com/in/hayliepomroy/  X: https://x.com/hayliepomroy    Enjoy our show? Please leave us a 5-star review on the following platforms so we can bring hope and help to others.   Apple Podcasts: https://podcasts.apple.com/us/podcast/hope-and-help-for-fatigue-chronic-illness/id1724900423 Spotify: https://open.spotify.com/show/154isuc02GnkPEPlWfdXMT   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d   Enjoy our show? Please leave us a 5-star review on the following platforms so we can bring hope and help to others.   Apple Podcasts: https://podcasts.apple.com/us/podcast/hope-and-help-for-fatigue-chronic-illness/id1724900423   Spotify: https://open.spotify.com/show/154isuc02GnkPEPlWfdXMT   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d   This podcast is brought to you by the Institute for Neuro-Immune Medicine. Learn more about us here.   Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM

Nicola Longo MD, PhD, and Mark Roberts, MD Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice.The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss vectors, different strategies, modes of administration and targets in gene replacement therapies.Mark Roberts, MDNow in the broader sense, gene replacement therapy seeks to actually deliver genetic material directly into the host cell to influence gene expression. In the most simple idea, one of course has a vector, this is most commonly but not exclusively a virus, which can then be given intravenously for example, and can hope to potentially correct the condition within the individual cells using novel transgenes. Suitable candidate conditions for this as examples of genetic conditions are now well understood. And crucially, this applies not only towards some more recessive, but dominant and even accident conditions.Across the piece, one can see for example, mitochondrial problems, spinal muscular atrophy as is well known, X-linked myotubular myopathy, Duchenne muscular dystrophy, a very common condition affecting one in 3000 male individuals, Pompe disease of course, an important focus of the meeting here, but other very common conditions, for example, cystic fibrosis, immunological conditions and perhaps obviously very crucial in early work on gene therapy, hemophilia.Let's now think about the approaches to gene therapy. One can seek to work at the DNA level and gene replacement. In essence, one is trying to put a new transgene through into the nucleus that will ultimately be transcribed and translated and produce the important functional protein that is lost. Gene editing which is a very exciting new technology or CRISPR technology actually seeks to actually modify in vivo the actual mutations that are responsible for the pathogenic production of abnormal proteins and correcting these and actually producing a more normalized protein.But of course there are also RNA approaches where one seeks to actually repair the mRNA transcripts copied from the mutated gene. For example, this may be a novel approach that could be extremely useful in myotonic dystrophy, a multisystem condition. When we talk about the viral vectors, predominantly we're talking about viruses. Those such as adenoviruses and AAV viruses which have the virtue of not integrating into the host genome or at least not in a large amount, and those which deliberately seek to integrate into host genome such as retroviral or lentiviral systems that may be particularly useful for ex vivo systems.There are of course other ways to get genetic payloads into the nucleus, various polymers, nanoparticles and even cell penetrating peptides. Nanoparticles in particular is certainly on the ascendant. That being said, in a recent review of the clinical trials in gene therapy, it was certainly the viral vectors that stood out both in direct gene replacement with lentivirus and AAV, but also actually as delivery systems, for example, for gene editing. An example of what one is seeking to do with AAV, so of course one seeking to remove the native DNA, insert the new transgene directly into the vector and of course keen to make sure that there's a high transmission into the capsid producing a recombinant AAV, which then can be given as a treatment and hopefully produce a therapeutic increase in the functional protein that is deficit in the disorder.In the next part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.

Nicola Longo MD, PhD, and Mark Roberts, MDNicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this 8-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th-7th 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.Mark Roberts, MDUndoubtedly, the immune system is a major issue in these patients. It would be fantastic if we could immunotolerize our patients and indeed prevent the rejection of the therapy. We've talked about the fact that these are viral vectors and of course there may be high seroprevalence of antibodies to these viral vectors, and it's very important in the pre-screening of patients who might be eligible to understand that at the beginning. These of course can have developed over the years and of course can be part of immunological memory and therefore extremely difficult and probably impractical to actually shift.On giving the treatment though as I think we're all aware there is this problem of the innate immunity and potential therefore for acute toxicities and then a learned or adaptive response with cytotoxic T cells and antibodies which may of course become high tighter neutralizing antibodies and potentially antibodies not only against the viral vector, even the functional protein, even the transgene are all theoretical possibilities with time. The capsid, the transgene, and even the protein product can all potentially induce an immunological event. Of course, all of these would lead to both potential patient changes and then a lack of efficacy of the treatment.Indeed, there have been some serious and indeed fatal problems in the gene therapy development program as I think we're all aware. Though many of these are thankfully been overcome. Spinal muscular atrophy has a gene therapy which is licensed, but there were early patients who actually had significant problems. A patient of just 6 months of age who developed kidney failure, two other patients who actually developed liver failure.In Duchenne muscular dystrophy, a very common condition, again there were significant issues and crucially in these patients who all have cardiomyopathy, it was heart failure and cardiac arrest that were big concerns and pulmonary edema and this was seen even with a CRISPR-based technology and is perhaps is best known but has been addressed the excellent myotubular myopathy patients, four patients died and crucially quite a long time after the gene therapy emphasizing the need to monitor these patients extremely carefully and these patients died of cholestatic liver failure albeit that they had a degree of liver dysfunction.That's changed our screening of course of patients, we're now all looking in myotubular patients for liver involvement and Rett syndrome as well. Now these immunoprophylaxis treatment regimes to hopefully try and reduce the immunological reaction against the gene are certainly evolving.This is just a summary of some of the other immunosuppressive regimes used in other disorders, for example, spinal muscular atrophy, but Pompe and MPS as examples of LSDs. Certainly these regimes will continue to evolve and are going to be very important in seeking to make sure that these treatments are effective. It reminds me somewhat of what's happened with enzyme replacement therapy that the use of these immunological strategies in infants has revolutionized the utility of those treatments in early patients.In the next part, Dr. Roberts will discuss lessons learned from gene therapy trials.

Nicola Longo MD, PhD, and Mark Roberts, MDNicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs.Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Dr. Roberts will discuss lessons learned from gene therapy trials.Mark Roberts, MDWhen we think about the challenges of actually doing clinical trials with these gene therapies, there's a huge development stage in terms of picking the right viral vector with the right surface receptor. That's a major piece of work. That can often take years. The preclinical work is obviously very important as indeed is understanding the natural history because it's really not practical to do placebo-controlled trials of gene therapies.In contrast to other studies, when we turn to phase 1 and phase 2, you'll notice that the patient numbers are often quite small. One is having to think carefully about surrogate measurements of response. Especially when in phase 3 studies, we may be thinking about withdrawing the existing, for example, enzyme replacement therapy because we believe the gene therapy will then be effective.That's just a few snapshots of where we've come and there's a lot more work to be done.In the next part, Dr. Longo will discuss the current treatment landscape and limitations in lysosomal disorders.

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight part podcast series. This is derived from the symposium that was presented at World Symposium 2025, in San Diego, California, on February 4th through 7th, 2025, and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established, and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Longo will discuss gene replacement therapy in lysosomal disorders.Nicola Longo MD, PhDLet's go back a second to gene therapy. Gene therapy obviously has the potential of answering many of the questions that we still have open in lysosomal disorder because they could restore the activity of the lysosome pretty much in the whole body, or at least in multiple tissues. As you have seen, gene therapy can be done ex vivo where we take cells from the affected patient, we correct the gene, or we put an extra gene that it is functional. Then we put them back by doing a bone marrow transplant, basically creating space for the cells that have been genetically modified to correct the lysosomal defect. The biggest approach this is done usually by lentiviruses that they integrate inside the genome.

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Longo will discuss ongoing gene therapies in lysosomal disorders.Nicola Longo MD, PhDI'm going to present to discuss some example of ongoing gene therapy for lysosomal disorder. There are gene therapy in development for both Fabry disease and some of this involve ex vivo gene therapy, many others involve systemic administration with an AAV, Gaucher disease type 1 that affect the periphery, and Gaucher disease type 2, where the replacement should occur within the central nervous system because this condition affects the brain. There is already one approved gene therapy for lysosomal disorder, which is for the early onset metachromatic leukodystrophy. This has been approved both in Europe and now even in the United States, which consists of ex vivo gene therapy with the administration of an extra gene that restore the function of the defective enzyme. Now there are many others that are ongoing for the same indication. There are gene therapy programs for GM1 and GM2 gangliosidosis, and at least one for Krabbe disease. It is important to know that some of these condition are actually included in the recommended uniform screening panel. Basically, we would have access to patients in a timely manner for some of these conditions. Then there are several gene therapy under development for the mucopolysaccharidoses, including MPS-IH, MPS-II, MPS-IIIA and MPS-IV.There are different type of lysosomal disorders, the one caused by mutation, integral membrane protein, not enzyme within the lysosome, but protein that are present on the membrane of the lysosome. This gene therapy that have been tested, it is for cystinosis, that it is caused by a defective lysosomal and for Danon disease, which is caused by a deficiency of an integral membrane part. Finally, one lysosomal disorder, which obviously seems a metabolic condition, but it is really not, is glycogen storage disease type 2 or Pompe disease, in which there is the intralysosomal accumulation of glycogen. There are several ongoing clinical trials to try to correct the problem in this condition.Now, I'm going to discuss some of the most advanced program in the lysosomal storage disorder. This include one for Fabry, which is on an accelerated approval pathway with phase 1 and 2 data, one for Gaucher disease type 1. Obviously, I'm going to discuss the one that has been already approved for metachromatic leukodystrophy. There is one for Hunter syndrome, and the difference of the one for Hunter syndrome, it is an example of the direct administration of gene therapy within the central nervous system.Finally, there is one ongoing for glycogen storage disease type 2 or Pompe disease in adult patients. In gene therapy for metachromatic leukodystrophy, it was the first gene therapy approved for lysosomal disorder in human, and this requires harvesting the CD34 cell from affected patient and then introducing the [inaudible 00:04:32] gene back in this cell, and then placing them back inside the patient again. This has been very effective in patients who were treated early, and obviously, the treatment needs to occur before there is irreversible brain damage in this patient.In the next part, Dr. Roberts and Longo will discuss treatment with gene therapies.

Tune in Friday, December 19, 2025 @ 7pm EST/4pm PST/6pm CST for the next “He Said, He Said, He Said Live!” A Look at the World from A Seasoned Black Man's Perspective…becauseone perspective isn't enough!” for “The Renaissance of Reggie Van Lee: Leadership, Legacy, and Living with Purpose” with special guest Reggie Van Lee.”Join us for our He Said, He Said, He Said Live Holiday Show, featuring an in-depth conversation with Reggie Van Lee, a global executive whose career bridges transformational leadership, corporate strategy, and cultural stewardship.Reggie Van Lee is an Executive Partner & Managing Director at AlixPartners, bringing more than three decades of experience advising corporations and boards through complexity and change. Prior to AlixPartners, he served as Chief Transformation Officer at the Carlyle Group, leading enterprise-wide initiatives across culture, structure, corporate strategy, diversity, and talent. Before that, he spent more than thirty years at Booz, Allen & Hamilton, retiring as an ExecutiveVice President focused on strategic transformation and high-performance organizations.Beyond the boardroom, Reggie's leadership extends deeply into mentorship, civic service, and the arts. He serves on the boards of the Women's Venture Capital Fund II, NationalCARES Mentoring Movement (Chair), Blair House Foundation, and the Coalition for African Americans in the Performing Arts (Chair). He is the Chair of the Washington, DC Commission on the Arts and Humanities, co-founded andchairs the Black Theatre Coalition and helped co-found the Gospel Music Haus Museum.A former Trustee of the Kennedy Center and member of the Tony Awards Nominating and Voting Board, Reggie has also served as Chair of Washington Performing Arts and Vice Chair of the Washington Ballet. His honors include being named one of the Top 25 Consultants in the World, a Washington Minority Business Leader, and Black Engineer of the Year. Reggie holds BS and MS degrees in Civil Engineering from MIT, has served on the MIT Corporation, and earned an MBA from Harvard University.This holiday closing episode goes beyond titles to explore leadership, legacy, joy, and living with purpose—and why those values matter now.New Episodes of “He Said, He Said, He Said” - Live stream Fridays, 7 p.m. EST on all theselinks: https://linktr.ee/hesaidhesaidhesaid FACEBOOK: facebook.com/hesaidhesaidhesaidlive RELIVE and SHARE special moments from "He Said, He Said, He Said" here: SHOW CLIPS (22) He Said, He Said,He Said - Live - YouTubeFOLLOW US —- CLICK LIKEand SUBSCRIBE to us @hesaidhesaidhesaidlive on YouTube and Instagram!#HeSaidHeSaidHeSaidLive #HolidayShow #ReggieVanLee #RenaissanceOfReggieVanLee #LeadershipWithPurpose #LegacyAndImpact #TransformationalLeadership #ExecutiveLeadership #PurposeDrivenLeadership #CulturalLeadership #MentorshipMatters #LivingWithIntention

It's official — with the swipe of President Donald Trump's pen, North Carolina’s Lumbee Tribe is now the 575th federally recognized tribe. Correspondent Matt Laslo has the story from Washington. Dozens of members of the Lumbee Tribe traveled from North Carolina to Washington to be a part of history this week. Tears were heard in the gallery after the U.S. Senate approved the measure granting the Lumbee federal recognition Wednesday. And after President Trump signed it into law Thursday, Lumbee Chairman John Lowery could barely contain his joy. “Weeping may endure for a night, but joy cometh in the morning, and our joy is here. It's here. We finally achieved what our ancestors fought so long and so hard to achieve.” There are roughly 60,000 members of the Lumbee, making it the largest Native American tribe east of the Mississippi River. North Carolina officials recognized the tribe after the Civil War in 1885, but not federal officials. U.S. Sen. Thom Tillis (R-NC) has helped lead the fight in the Senate in recent years. “Yeah, we’re a little bit excited after 137 years, on their part, about 40 years on Senate members part, it’s good to see it get done.” Tillis is retiring at the end of his term next year, but he says the decade-long battle for federal recognition for the Lumbee shows Washington isn't totally broken — even if the tribe and North Carolina lawmakers fought an uphill battle for years now. “A lot of educating and just, you know, prioritize the way. This is the way this works, right? You come in, you use leverage, you have discussions, you build a case. I think that’s what happened. I really appreciate the delegation. This was a well-coordinated effort.” Back in 1956, Congress partially recognized the Lumbee, but that left the tribe locked out of federal health services. And it meant the tribe couldn't operate casinos or marijuana dispensaries like other tribes. Chairman Lowery says it's a new day for the Lumbee. “The 1956 act, which left us in legal limbo, is now erased. It is no more and we are now fully, fairly recognized.” The Eastern Band of Cherokee Indians fought the federal recognition of the Lumbee, which passed as a part of an annual $900 billion defense authorization bill. The Prairie Band Potawatomi Nation in Kansas issued a statement this week to its tribal members about a U.S. Immigration and Customs Enforcement (ICE) contract after the deal was met with public scrutiny. In a video statement, Chairman Joseph Rupnick said the Nation and its subsidiaries have fully divested from the ICE contract. “As a result, Prairie Band, LLC is no longer a direct or indirect owner or participant in, or otherwise affiliated with, any ICE-related projects, contracts, or operations. In our next General Council meeting in January, Tribal Council plans to further address the steps we will take to ensure that our Nation's economic interests do not come into conflict with our values in the future.” Tribal citizens from across the U.S. have raised concerns about ICE and the Trump administration's immigration policies. Native people have also reported being confronted by ICE, including actress Elaine Miles, who has been sharing her story with media outlets about her run-in with ICE agents in November. (Courtesy Elaine Miles) U.S. Sen. Brian Schatz (D-HI), Vice Chairman of the Senate Committee on Indian Affairs, U.S Sen. Patty Murray (D-Wash.), Vice Chair of the Senate Appropriations Committee, and 10 of their Senate colleagues recently sent a letter to Homeland Security Secretary Kristi Noem about reports of ICE encounters with tribal citizens. They are urging her to develop policy and trainings to recognize tribal IDs and requested a response by January 11. Get National Native News delivered to your inbox daily. Sign up for our daily newsletter today. Download our NV1 Android or iOs App for breaking news alerts. Check out the latest episode of Native America Calling https://www.nativeamericacalling.com/friday-december-19-2025-native-music-in-2025/

Send us a textOn this week's episode of the WTR Small-Cap Spotlight, Chris Cooper, the new CEO of XCF Global (NASDAQ: SAFX), joined Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainable Investing Analyst at Water Tower Research. Cooper shares his extensive aviation and energy industry journey from aspiring pilot to President of Neste US (and more!) and tells us what ultimately attracted him to join as CEO of XCF Global. The conversation covers XCF's innovative approach to transforming waste and residue feedstocks into SAF, its modular and scalable refinery model, major strategic partnerships like with Phillips 66, the aviation industry's path to decarbonization, and SAF's role as the only practical and immediate solution. Cooper discusses policy impacts, market challenges, and why XCF is well placed to capitalize on growth opportunities with expansion and new facilities in the US and Australia. 

Vice-Chair of the Make-A-Wish Iowa Board Dan Huitink and Derek De Haan with 100+ Men Red Rock discuss the 100+ Men Red Rock's check donation to Make-A-Wish Iowa on Thursday.

Nury Turkel, FORMERLY Vice Chair of the US Commission on International Religious Freedom, discusses his book No Escape. He details the sadistic rule of Chinese official Zhu Hailun and the persecution of scholar Abduvali Ayup, illustrating the terror and brutality used to erase Uyghur culture and language. 1900 DOWAGER EMPRESS QING DYNASTY

Property taxes have been the buzz across Ohio, and this episode breaks down what's driving the conversation and what recent reforms really mean for homeowners. Anastasia and Andrew sit down with State Representative David Thomas, Vice Chair of the House Ways and Means Committee and sponsor of all four property tax reform bills that recently passed out of the Statehouse. Representative Thomas shares what pushed him to lead this effort, the core issues in Ohio's property tax system, and how the latest reforms aim to provide relief while maintaining critical funding for schools and local governments. Tune in to hear what's changed, what's coming next, and what homeowners and REALTORS should know moving forward.In This Episode, We Cover:Rep. Thomas's background and what led him to champion property tax reformWhy property taxes have become such a major issue across OhioThe core problems with Ohio's current property tax structureA breakdown of the four property tax reform bills that passed the StatehouseWhat additional reforms could be considered in the futureWhat REALTORS should know — and share — as these reforms move forward

On Episode 59 of the Stroke Alert Podcast, host Dr. Negar Asdaghi is joined by Dr. Eva Mistry, Stroke Associate Editor and Vice Chair of Research and Divisional Director of Vascular Neurology at the Department of Neurology and Rehabilitation Medicine at the University of Cincinnati, for the 2025 Ralph Sacco Review of Top Cerebrovascular Research. In honor of the late Dr. Ralph L. Sacco, former Editor-in-Chief of Stroke, who died in January 2023, Drs. Asdaghi and Mistry review some of the top cerebrovascular science published in any journal or presented at any scientific forum throughout the past year. For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20251216.704704

Tech portfolio manager Dan Niles explains why there could soon be a near-term bottom in the weighed down AI trade. Then former Fed Vice Chair Richard Clarida reacts to the November CPI print and weighs in on the race for the next Fed chair. Plus, the CEO of Joby Aviation, on plans to double U.S. production by 2027 and expand its network of takeoff and landing sites known as “vertiports.” Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Greetings, and welcome back to the podcast. This episode we are joined by Mr. Vern Yu - CEO of AltaGas - a TSX listed midstream & utilities company with a market cap of ~$13 billion. As President and Chief Executive Officer, Vern Yu leads the development and execution of AltaGas' strategy, oversees operations and manages the business and affairs of AltaGas.Vern is an experienced executive with a proven track record of success across the energy infrastructure value chain including within North American Midstream and Utilities markets being AltaGas' core focus areas. Vern joins AltaGas after a successful three-decade career at Enbridge Inc., most recently serving as Executive Vice President, Corporate Development, Chief Financial Officer and President, New Energy Technologies. Prior to that, Vern held various commercial, operational, and financial roles including serving as Executive Vice President, President Liquids Pipelines and as Executive Vice President and Chief Development Officer, where he played a leading role in securing more than $30 billion in new growth projects, completion of major pipe replacement projects, leading entry into new markets, and various acquisitions.Vern holds a Master of Business Administration degree in Finance from the University of Toronto, as well as a Bachelor of Science degree in Applied Science from Queen's University. He previously served as the Vice Chair of the Alberta Cancer Foundation's Board of Trustees and served on the Boards of DCP Midstream, Énergir Inc. and Calgary Economic Development.Among other things we learned about Gas Utilities, LPG Markets & Asian Export Opportunities.Enjoy.Thank you to our sponsors.Without their support this episode would not be possible:Connate Water SolutionsATB Capital MarketsEPACAstro Oilfield Rentals AmbyintBunch ProjectsSupport the show

Send us a textOn this week's episode of the WTR Small-Cap Spotlight, John Gibson, CEO of Nauticus Robotics (NASDAQ: KITT), joined Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainable Investing Analyst at Water Tower Research. The conversation covers KITT's autonomous underwater vehicle (AUV) strategy, technology, and milestones. Gibson highlights KITT's focus on delivering efficiency, safety, and cost savings and discusses how the new relationship with Forum Technologies (FET) will accelerate KITT's manipulator strategy. Key achievements include successful acquisitions, expanded testing facilities, software retrofits for existing vehicles, and manufacturing partnerships to accelerate growth. Discussion covers capital strategy, plans for the ELOC, and deep-sea mineral exploration strategy. John also emphasizes a disciplined approach to financial management, shareholder value, and a shift from surviving to thriving as Nauticus enters 2026.

Send us a textJoin Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer at WTR, and Peter Gastreich, Senior Energy Transition and Sustainability Analyst, as they discuss Peter's recent report on Abundia Global Impact Group (AGIG) including: 1) AGIG's waste-to-value approach that redirects materials from landfills and incineration; 2) strategy for converting hard to recycle waste plastics and waste woody biomass into high value fuels and chemicals like sustainable aviation fuel (SAF); 3) AGIG's access to proprietary pyrolysis technologies; 4) recent milestones including Cedar Port facility groundbreaking on the Houston Ship Channel and newly announced strategic partnerships for renewable fuel development; 5) recent capital raises and strengthened balance sheet; and other topics.

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established, and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Dr. Roberts will discuss lysosomal disorders and the potential for gene therapies.Mark Roberts, MDI'm going to give an overview of what is gene therapy, emphasizing the current challenges and the development issues and needs that there will be as we try and enable gene therapy for our patients, particularly those with lysosomal storage disorders.I'm going to try and make a case for why lysosomal storage disorders are an extremely good group of conditions for the potential benefits of gene modifying therapies. Firstly, whilst we all recognize that these conditions are inherently individually rare, they're certainly severe. Collectively, with over 70 LSD disorders, 1 in 5,000 may be afflicted by these conditions ultimately in their life and can be detected, for example, by newborn screening programs.Secondly, there's certainly a significant clinical burden with these patients with the current standard of care, so a large unmet need exists. Existing enzyme replacement therapies have undoubtedly changed the natural history of many of these conditions, but there are limitations and often initial benefits and later deteriorations.Unfortunately, for most lysosomal storage disorders, it's only symptomatic treatments and indeed, care that is available for these patients with no specific treatment. Thirdly, these conditions are extremely well-characterized, monogenic singleton and problems of inborn errors of metabolism. We know the functional protein that is deficient in these conditions. Because of that, and knowing that these are critical for lysosomal function, and using preclinical models, we can model the potential benefits of gene therapies very well in a number of systems, including, of course, soon, muscle chip experiments as well.Finally, with these conditions, they may potentially be really useful targets whilst not perhaps curing the condition, at least ameliorating the phenotype, and enabling the addition of other treatments as well, potentially. I've noted, some of these therapies can be directly delivered to certain tissues, so muscle tissue, which is my main interest, but also, crucially, the central nervous system, which is very important when we consider ameliorated phenotypes, for example, treated by enzyme replacement therapy, but where the children who become the adults have significant learning disability as a major component to their problems.In the next part, Dr. Roberts will discuss vectors, different strategies, modes of administration, and targets in gene replacement therapies.

Would stricter gun laws have prevent the horror that was the Bondi Beach terror attack? That's a question now being looked at as Australia's leaders commit to putting our current gun laws under the microscope. But will tightening restrictions have real world impact? We ask an expert. And in headlines Boris Gurman and wife Sofia were caught on dash cam courageously confronting the two alleged Bondi gunmen before being killed; AFP Commissioner says "It appears the alleged killers were interested only in a quest for a death tally"; To Silvani, the son of former AFL player Steve Silvani will learn his fate today, as he faces a potential maximum 25 year jail term for rape; Angelina Jolie has shared her mastectomy scars in a new photoshoot THE END BITS Donate blood, find your nearest donation centre here Support independent women's media Check out The Quicky Instagram here GET IN TOUCHShare your story, feedback, or dilemma! Send us a voice note or email us at thequicky@mamamia.com.au CREDITS Hosts: Taylah Strano & Claire Murphy Guests: Prime Minister Anthony Albanese Roland Browne, Lawyer & Vice Chair of Gun Control Australia Audio Producer: Lu Hill Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

From the Evidence-based Perioperative Medicine (EBPOM) Conference in Dingle, Ireland, Desiree Chappell and Sol Aronson are joined by Alex Mittnacht, President and Founding Director, International Academy of Cardiac Anaesthesiologists (IACA), and Vice Chair of Anesthesiology and Chief of Pediatric and Adult Cardiac Anesthesia at Westchester Medical Center, New York, USA. Dr Mittnacht shares his fascinating professional journey and delves into the intricacies of paediatric cardiac anaesthesia, including its evolving training pathways, workforce challenges, and the increasing demands for specialized care. Discover how multidisciplinary care and the proper training of anaesthesiologists are crucial for effective patient management, particularly for those with congenital heart disease. What is future of this essential medical specialty?

What happens when passion meets purpose in Tampa Bay? On this episode of "Money" Market, Owen sits down with Mike Griffin, Vice Chair of the USF Board of Trustees and Co-Head of Florida for Savills, to talk about the momentum transforming the region. From shaping USF's $400 million on-campus stadium to advising major companies on growth strategies, Mike's influence reaches from the boardroom to the community tailgate. He shares how collaboration between business and education is fueling Tampa's evolution into a national player. Owen and Mike dig into how real estate, leadership, and civic engagement all work together to drive progress. They explore what makes Tampa's market more resilient than most and how the city's energy keeps attracting talent and investment. With insights on everything from flexible office space to long-term growth, Mike reveals the mindset behind smart development and sustainable success. It's an inside look at how Bulls spirit and business savvy are shaping Tampa's future.   WATCH NEXT: TAKING THE FALL: THE LIFE OF A STUNT PRO W/ STUNT COORDINATOR AND ENTREPRENEUR KEVIN REGO https://youtu.be/5OXGfOfJkiI SUBSCRIBE: https://www.youtube.com/channel/UCz_7yNs7dOuyKApAkohqJIQ   Follow The "Money" Market Podcast here: Spotify: https://open.spotify.com/show/6e7E0DaJZQkuw339G7nGI4?si=27d047641a1d4b17 Apple Podcasts: https://podcasts.apple.com/us/podcast/the-money-market-podcast/id1733948143 Instagram: https://www.instagram.com/moneymarketpodcast Facebook: https://www.facebook.com/moneymarketpodcast Website: https://moneymarketpodcast.com   The Bank of Tampa | Member FDIC   Check out Savills: https://www.savills.us

In this episode, Cathleen McCabe, MD, and Laura Enyedi, MD, chat with guest Erin M. Shriver, MD, FACS, an ophthalmologist and clinical professor of ophthalmology and visual sciences and the Jim O'Brien Gross and Donnita Gross Chair of Ophthalmology at the University of Iowa, about how we can better advocate for patients. ●       Welcome to this episode 0:11 ●       Introducing Erin M. Shriver, MD, FACS 0:35 ●       Tell us a little bit about where you are now and how you got there 1:45 ●       Choosing to look at advocacy and public health issues 5:36 ●       Research on intimate partner violence 6:15 ●       Do you think doing surgery is giving patients/women control over their body? 9:20 ●       The Intimate Partner Violence Toolkit 10:08 ●       Speaking on sensitive topics with patients 10:51 ●       Your new role of Vice Chair of Faculty Affairs 11:31 ●       Having standardized metrics 13:54 ●       Gender disparities 14:21 ●       Global mentorship of other women ophthalmologists 16:06 ●       Stronger together, virtually and globally 19:40 ●       The importance of listing 'being a mom' on your CV 20:20 ●       Thank you! 24:24 Laura Enyedi, MD, is a professor of ophthalmology and pediatrics at Duke Eye Center and medical director of South Durham Ophthalmology in North Carolina. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, Florida. Erin M. Shriver, MD, FACS, an ophthalmologist and a clinical professor of ophthalmology and visual sciences and the Jim O'Brien Graoss and Donnita Gross Chair of Ophthalmology at the University of Iowa. Find the Intimate Partner Violence Toolkit here.  We'd love to hear from you! Send your comments/questions to podcast@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The hosts and guests report no relevant financial disclosures.

Nearly half of trainee GPs this year are from universities abroad amid Ireland's family doctor shortage.GP training places have increased in recent years in the hope that they will act as a pipeline to produce more who will work in this country delivering care to patients.It's no secret that Ireland has been suffering from GP shortages for some time now, but will more training spaces actually fix this?To discuss this further, Ciara Doherty is joined by Dr Madeleine Ní Dhálaigh, Vice Chair of the GP Committee of the IMO and GP in Castlerea.

I'm a paralegal professional with over 20 years of civil litigation experience that advocates for people's legal rights under the law as a consultant at Ms. Camay International. I'm a motivational speaker who presents webinars on financial estate literacy, body positivity and addressing bullying in the workplace.I'm the President of the National Workplace Bullying Coalition and the Vice-Chair of the Paralegal Division at the Nevada State Bar and have dedicated my life's work to my community as “The People's Advocate” passionate about making and difference and impacting the world.I founded my non-profit organization, Local Vegas Legal Support, Inc., to champion the legal support professional and bridge the gap between local Las Vegas youth and their access to a career in the legal field.Fun Facts About Me:✅ Crowned Miss Plus World Intercontinental Royal Ambassador✅ Presented with the Volunteer Service Award by President Barak Obama✅ Founding “Boss Lady” on “The Boss Ladies Breakroom” on YouTube✅ Rock fashion runways with my King around the country✅ Nick-named “class cheerleader” in Les Mills Body Pump✅ Raised in Italy and Greecehttps://www.mscamayinternational.com/attorneyshttps://www.linkedin.com/in/camaymcclure/ ***********Susanne Mueller / www.susannemueller.biz TEDX Talk, May 2022: Running and Life: 5KM Formula for YOUR Successhttps://www.youtube.com/watch?v=oT_5Er1cLvY Join Substack: https://substack.com/@susannemuellernyc?Enjoy one coaching session for free if you are a yearly subscriber. 700+ weekly blogs / 500+ podcasts / 1 Ironman Triathlon / 5 half ironman races / 26 marathon races / 4 books / 1 Mt. Kilimanjaro / 1 TEDx Talk

Send us a textThis week on the WTR Small-Cap Spotlight, Ruella Menezes , Director of Energy with the Management Consulting Practice at Kline & Company , sits down with Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainable Investing Analyst at Water Tower Research. Together, they dive into the game-changing potential of sustainable aviation fuel (SAF) for slashing airline emissions, zero in on what's fueling the explosive growth in SAF demand, and unpack the real-world hurdles of getting new projects off the ground. The conversation also takes on the tough question of how airlines can afford SAF when it's still much pricier than fossil jet fuel, explores feedstock bottlenecks and the rise of new production methods, and breaks down the biggest risks ahead—from the need for unified policy to the crucial role of industry collaboration and ongoing innovation.

Dr. Julio Friedmann of Carbon Direct joins Tom Heintzman, Vice Chair, Energy and Climate Finance to discuss the role of carbon capture and storage (CCS) in decarbonizing power, the case for CCS deployment in natural gas-fired generation, and the opportunities and benefits for businesses deploying CCS initiatives. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

David Aaker, known as the "Father of Modern Branding," is Vice-Chair at Prophet and one of the world's leading authorities on brand strategy. Creator of the Aaker Brand Vision Model, he has shaped how organizations build and manage enduring brands. His contributions have earned him induction into the American Marketing Association Hall of Fame and the Sheth Foundation Medal for Exceptional Contribution to Marketing Scholarship and Practice. Aaker has authored 18 books and hundreds of articles, selling over one million copies worldwide and translated into 18 languages. His influential works, including Building Strong Brands, Brand Portfolio Strategy, Brand Relevance, and Aaker on Branding, provide timeless guidance for marketing leaders seeking to drive growth and brand relevance. Professor Emeritus at the Haas School of Business, UC Berkeley, Aaker remains an active consultant, keynote speaker, LinkedIn Influencer, and blogger at davidaaker.com, inspiring executives globally with practical insights on brand leadership and growth. During the show we discuss: How AI uncovers deep customer insights and predicts emerging trends How to design value propositions that truly resonate with customers Connecting brand strategy to measurable demand-generation outcomes How integrated marketing planning aligns channels and touchpoints Steps to optimize media strategies in today's complex marketplace The core components of a modern marketing operating model Creating a compelling value exchange between brands and customers Measuring success across brand-building and demand-driving efforts The role of creative strategy in activating brand and demand strategies How organizations can future-proof their marketing capabilities Resources: https://www.linkedin.com/in/davidaaker/  https://www.amazon.com/Aaker-Branding-Playbook-Building-Strong/dp/163698665X  

CES 2026: AI and Innovation Take Center Stage with Gary J. Shapiro https://www.cta.tech/people/gary-shapiro/ https://www.ces.tech/ About the Guest(s): Gary J. Shapiro is the Vice Chair of the Consumer Technology Association (CTA), a leading trade association representing U.S. consumer technology industries. He has been a pivotal figure in the tech industry since 1991, serving in various leadership roles at CTA and significantly contributing to the growth of the CES® show, the largest and most influential tech event in the world. Gary is also a lawyer, prolific author, and recognized lobbyist, with several influential books and over 1,300 op-eds to his name. His efforts have positioned him as a key voice in technology and policy discussions. Episode Summary: Get ready to dive into the latest in consumer technology with the inimitable Gary Shapiro on this episode of The Chris Voss Show Podcast. In an engaging conversation marking his eighth guest appearance, Gary talks with Chris about the upcoming CES 2026, highlighting the groundbreaking innovations set to transform industries and impact global markets. As Vice Chair of the Consumer Technology Association, Gary offers invaluable insights into tech trends shaping the future, including the pervasive growth of AI and robotics, and the show's focus on manufacturing and startups. Gary and Chris navigate the complex dynamics of tech advancements and market demands, exploring themes such as AI's transformative role in various sectors, the emergence of robotics in modern industries, and the vital intersection of technology with healthcare and manufacturing. This discussion also shines a spotlight on CES 2026, celebrated for its sprawling exhibits and visionary content, serving as a global stage for innovation with thousands of attendees discovering the latest breakthroughs from startups and tech giants alike. Don’t miss this enlightening episode brimming with expert insights and forward-thinking discussions. Key Takeaways: CES 2026 will prominently feature advances in AI, with dedicated areas like The Foundry exploring AI, cybersecurity, and quantum computing. Robotics is a burgeoning field at CES, impacting industries from manufacturing to healthcare. The CES show serves as a launchpad for startups worldwide, with the Eureka Park section showcasing groundbreaking innovations and attracting investors. The conversation extends to political influence on tech and manufacturing, with Gary offering nuanced views on trade policies and production strategies. Gary emphasizes the ineffable value of face-to-face interactions at CES for fostering business deals and innovative partnership opportunities. Notable Quotes: “The guy who hired me started in New York and moved to Chicago. Got pretty cold one January there, and they were the first big business event to move to Las Vegas.” – Gary Shapiro “AI will be pervasive throughout the show… it’s definitely, if there’s one core technology underlying the CES, it’s AI.” – Gary Shapiro “If there’s one category, it would be startups. We have over a thousand different startups…” – Gary Shapiro “CES has several thousand exhibitors from all over the world.” – Gary Shapiro “As a country, we’re on our way to finding better ways to do things.” – Gary Shapiro

Pool Pros text questions hereOn this Talking Pools episode, host Natalie Hood, Director of Education and Network Development for The Grit Game, sits down with Jodi O'Grady, Director of Commercial Sales for API Water and long-time industry chemist, to unpack one of the most misunderstood topics in pool care: specialty chemicals.Chlorine gets all the attention, but oxidizers, enzymes, and flocculants quietly decide whether your water is comfortable, clear, and compliant—or a cloudy, smelly headache full of disinfection byproducts and complaints. Jodi draws on decades with Taylor Water Technologies and her work on PHTA's Technical Advisory Council to bust myths, explain the science in plain language, and show how specialty products can support (not replace) chlorine to keep pools safer and easier to manage.If you've ever wondered whether non-chlorine shock actually does anything, if enzymes are all “basically the same,” or what Flock It Friday is really about, this episode connects the dots.In This Episode, You'll Learn:Chlorine's job vs. specialty chemicals' jobWhy chlorine (or bromine/PHMB) is irreplaceable as a sanitizer and must be EPA-registered to be counted as such.The difference between sanitizing (killing pathogens like Pseudomonas and brain-eating amoeba in properly chlorinated water) and oxidizing (burning off non-living contaminants).Why “chlorine can be replaced by specialty chemicals” is a myth—and how crypto is a different beast entirely.Non-chlorine oxidizers: the quiet workhorseReal-world impact of high chlorine levelsEnzymes: not “all the same”Myth-busting with real storiesFlock It Friday and how flocculants actually workClarity as a safety standard, not a luxuryThe payoff for pros and operatorsGuest Info – Jodi O'Grady, API WaterDirector of Commercial Sales, API WaterNearly 30 years in the pool industry, starting with Taylor Water Technologies (a Fluidra brand)Chemistry degree and long-time volunteer with PHTA, currently Vice Chair of the Technical Advisory Council, with prior work on the Recreational Water and Air Quality Committee.Jodi is available for follow-up questions and industry conversations via LinkedIn and direct contact (details provided in the episode outro).Host Info – Natalie HoodDirector of Education and Network Development, The Grit Game, and regular host on the Talking Pools Podcast, focused on education, professional development, and giving pool pros real-world tools they can use on deck tomorrow. Support the showThank you so much for listening! You can find us on social media: Facebook Instagram Tik Tok Email us: talkingpools@gmail.com

Send us a textOn this week's episode of the WTR Small-Cap Spotlight, Jim Deller, CEO of ClearSign Technologies (NASAQ: CLIR), joined Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainable Investing Analyst at Water Tower Research to discuss: 1) CLIR's patented ultra-low emissions burner technology for industries like oil refineries and petrochemical plants; 2) how CLIR's burners help clients meet strict NOx regulations globally without expensive post-combustion equipment; 3) key partnerships that boost manufacturing and credibility; 4) recent milestones like large commercial orders and the launch of a flexible-fuel 100% hydrogen burner; 5) expanding high margin aftermarket sales; and 6) CLIR's asset-light model approaching break-even profitability.

Federal Reserve is meeting to make its interest rate decision after the government shutdown delayed key economic data. Today on the show, we talk to the former Vice Chair of the Fed, Lael Brainard, about what she would do with interest rates in this critical yet foggy economic moment.Related episodes: A little doomsday feeling is weighing on the economyCan ... we still trust the monthly jobs report?For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at plus.npr.org. Fact-checking by Sierra Juarez. Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In this episode of Behind the Knife, the minimally invasive surgery (MIS) team dives deep into the evolving field of common bile duct exploration (CBDE). From the historical context of laparoscopic approaches to the latest advances including robotic-assisted techniques, Drs. Shaina Eckhouse, James Jung, Zachary Weitzner, and Joey Lew discuss key evidence shaping modern practice. Listeners will learn about indications and anatomy guiding trans-cystic versus trans-choledochal approaches, practical tips for safe stone clearance, and critical considerations around learning curves and team coordination for robotic procedures. The episode also highlights important studies comparing single-stage laparoscopic CBDE with staged ERCP and cholecystectomy, emphasizing outcomes such as stone clearance, pancreatitis rates, and hospital length of stay. This comprehensive overview is a must-listen for MIS and acute care surgeons interested in optimizing the management of choledocholithiasis and streamlining patient care with minimally invasive techniques. Hosts:  - Shaina Eckhouse, MD, Bariatric Surgery Medical Director and Vice Chair of Clinical Operations, Department of Surgery, Duke University - James Jung, MD, PhD, Assistant Professor of Surgery, Duke University - Zachary Weitzner, MD, Minimally Invasive and Bariatric Surgery Fellow, Duke University, @ZachWeitznerMD - Joey Lew, MD, MFA, Surgical resident PGY-3, Duke University, @lew__actually Learning Goals:  By the end of this episode, listeners will be able to: -  Describe the historical approaches to managing choledocholithiasis, including staged interventions and the evolution toward single-stage laparoscopic common bile duct exploration (CBDE). -  Summarize key clinical evidence comparing CBDE and ERCP, including landmark studies and meta-analyses evaluating outcomes, complications, and trends over time.​ - Distinguish between transcystic and transcholedochal approaches to CBDE, explaining indications, contraindications, and technical nuances for each technique.​ -  Identify appropriate candidates for transcystic exploration based on cystic duct anatomy and stone characteristics.​ - Recognize the impact of newer surgical technologies—such as digital choledochoscopy, Spyglass, and robotic platforms—on CBDE practice, efficiency, and safety.​ - Discuss the importance of multidisciplinary teamwork, preparation, and perioperative planning for successful CBDE, particularly in complex or altered anatomy cases.​​ - Appraise the learning curve and quality of evidence for new CBDE procedures, outlining the need for mentorship, ongoing training, and knowing when to collaborate with GI or hepatopancreaticobiliary (HPB) surgery.​ - Outline approaches and bailout strategies for challenging cases, including patients with surgically altered anatomy and use of adjuncts such as intraoperative cholangiography (IOC), feeding tube placement, and Fanelli stents.​​ - Evaluate safety outcomes and limitations associated with robotic-assisted CBDE and single-stage management, incorporating recent data from population-based studies.​ -  Reflect on strategies for tailoring CBDE techniques to individual patient anatomy, surgeon experience, and available resources, advocating for evidence-based practice and continuous learning. References: -  Giurgiu DI, Margulies DR, Carroll BJ, et al. Laparoscopic Common Bile Duct Exploration: Long-term Outcome. Arch Surg. 1999;134(8):839-844. doi:10.1001/archsurg.134.8.839 https://pubmed.ncbi.nlm.nih.gov/10443806/ -  Lyu Y, Cheng Y, Li T, Cheng B, Jin X. Laparoscopic common bile duct exploration plus cholecystectomy versus endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy for cholecystocholedocholithiasis: a meta-analysis. Surg Endosc. 2019;33(10):3275-3286. doi:10.1007/s00464-018-06613-w https://pubmed.ncbi.nlm.nih.gov/30511313/ - Bekheit M, Smith R, Ramsay G, Soggiu F, Ghazanfar M, Ahmed I. Meta‐analysis of laparoscopic transcystic versus transcholedochal common bile duct exploration for choledocholithiasis. BJS Open. 2019;3(3):242-251. doi:10.1002/bjs5.50132 https://pubmed.ncbi.nlm.nih.gov/31183439/ - Cironi K, Martin MJ. Reclaim the duct! Laparoscopic common bile duct exploration for the acute care surgeon. Trauma Surg Acute Care Open. 2025;10(Suppl 1). doi:10.1136/tsaco-2025-001821 https://pubmed.ncbi.nlm.nih.gov/40255986/ - Zhang C, Cheung DC, Johnson E, et al. Robotic Common Bile Duct Exploration for Choledocholithiasis. JSLS J Soc Laparosc Robot Surg. 2025;29(1):e2024.00075. doi:10.4293/JSLS.2024.00075 https://pubmed.ncbi.nlm.nih.gov/40144383/ - Kalata S, Thumma JR, Norton EC, Dimick JB, Sheetz KH. Comparative Safety of Robotic-Assisted vs Laparoscopic Cholecystectomy. JAMA Surg. 2023;158(12):1303-1310. doi:10.1001/jamasurg.2023.4389 https://pubmed.ncbi.nlm.nih.gov/37728932/ Ad Disclosure: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

I'm a paralegal professional with over 20 years of civil litigation experience that advocates for people's legal rights under the law as a consultant at Ms. Camay International. I'm a motivational speaker who presents webinars on financial estate literacy, body positivity and addressing bullying in the workplace.I'm the President of the National Workplace Bullying Coalition and the Vice-Chair of the Paralegal Division at the Nevada State Bar and have dedicated my life's work to my community as “The People's Advocate” passionate about making and difference and impacting the world.I founded my non-profit organization, Local Vegas Legal Support, Inc., to champion the legal support professional and bridge the gap between local Las Vegas youth and their access to a career in the legal field.Fun Facts About Me:✅ Crowned Miss Plus World Intercontinental Royal Ambassador✅ Presented with the Volunteer Service Award by President Barak Obama✅ Founding “Boss Lady” on “The Boss Ladies Breakroom” on YouTube✅ Rock fashion runways with my King around the country✅ Nick-named “class cheerleader” in Les Mills Body Pump✅ Raised in Italy and Greecehttps://www.mscamayinternational.com/attorneyshttps://www.linkedin.com/in/camaymcclure/ ***********Susanne Mueller / www.susannemueller.biz TEDX Talk, May 2022: Running and Life: 5KM Formula for YOUR Successhttps://www.youtube.com/watch?v=oT_5Er1cLvY 700+ weekly blogs / 500+ podcasts / 1 Ironman Triathlon / 5 half ironman races / 26 marathon races / 4 books / 1 Mt. Kilimanjaro / 1 TEDx Talk

Trumps neue Sicherheitsstrategie schockt Europa - ist sie auch ein Geschenk für die AfD?Paul spricht mit Benedikt Franke, dem Vice-Chair und CEO der Münchner Sicherheitskonferenz, über das 33-seitige Dokument aus dem Weißen Haus: Wie Donald Trump die Grundlagen der US-Außenpolitik umbauen will, warum die EU im Papier zum Feindbild wird und was das für NATO, Ukraine-Krieg und Europas Sicherheit bedeutet. Und natürlich: Ob Trump wirklich „patriotische Parteien“ wie die AfD stärkt - oder ob Europa sich seine Schwäche nur einreden lässt.Wenn euch der Podcast gefällt, dann lasst gerne Like & Abo da! Ihr habt Fragen, Kritik oder Themenvorschläge? Schreibt an ronzheimer@axelspringer.comPaul auf Instagram | Paul auf XUnd ganz neu: Paul jetzt auch auf YouTube!Redaktion: Filipp Piatov & Lieven JenrichExecutive Producer: Daniel van Moll Hosted on Acast. See acast.com/privacy for more information.

In this episode, Dr. Ardeshir Rastinehad, Vice Chair of Urology at Northwell's Lenox Hill Hospital and System Director for Prostate Cancer at Northwell Health, discusses emerging trends and breakthroughs in prostate cancer screening, diagnosis, and treatment. He explains the focal therapy process—including cryotherapy—and shares insights on the mission and impact of the Focal Therapy Society.

Presidential, CongressionalOllie is the first blind person and individual with a visible disability ever to be elected to the City Council since West Covina's founding in February 1923.Ollie Cantos is Chair Emeritus of Disability Belongs's Board of Directors. Cantos has been active in the civil rights arena since 1990.  OHe is Special Assistant to the Assistant Secretary for Civil Rights at the U.S. Department of Education, Attorney Mentor for the American Bar Association Commission on Disability Rights, and Member of the U.S. Coast Guard Auxiliary.Past positions include Staff Attorney and Director of Outreach and Education at the Disability Rights Legal Center, General Counsel and Director of Programs at the American Association of People with Disabilities, Special Assistant and later Special Counsel to the Assistant Attorney General for Civil Rights at the U.S. Department of Justice, and Associate Director for Domestic Policy at the White House under President George W. Bush. Prior leadership posts include Vice Chair of the President's Committee for People with Intellectual Disabilities, Vice President of the Virginia Organization of Parents of Blind Children, Legal Officer for the Coast Guard Auxiliary, Vice President of the Legal Aid Foundation of Los Angeles, But Ollie is most grateful for his adoption of three blind triplet boys – Leo, Nick, and Steven.  Their compelling story has been told by National Public Radio, PEOPLE Magazine, The Washingtonian Magazine, USA Today, and videos that went viral on NowThis.com, HeartThreads.com, and others. In addition to local media coverage, they were featured as Persons of the Week on ABC's World News Tonight with David Muir In December 2017 for attaining the coveted rank of Eagle Scout as part of Boy Scouts of America. Their story has now reached a grand total of more than 53 million views.

Sylvie Legere sits down with Dr. John Prunskis to explore the intersection of artificial intelligence and pain management. This episode unpacks the role of AI in identifying and treating chronic pain, particularly through innovative therapies like spinal cord stimulation. Dr. Prunskis shares his expertise on how AI is not only enhancing patient care but also transforming how healthcare is delivered, with a specific focus on reducing dependency on opioids. Dr. Prunskis discusses the mechanism of spinal cord stimulation, a procedure leveraging AI to dynamically interact with a patient's activity, offering personalized, non-invasive pain relief. By implementing AI, patients experience improved quality of life without the irreversible changes caused by traditional surgeries. The conversation also touches on potential hurdles, regulatory frameworks, and the exciting future of AI in healthcare, setting the stage for broader discussions at The Policy Circle Summit on AI's role across sectors.  Dr. John Prunskis Dr. John V. Prunskis, MD, FIPP, is a double-board-certified interventional pain physician internationally recognized for his leadership in pain management, regenerative medicine, and healthcare innovation. He is the founder and Chief Medical Officer of the Illinois Pain & Spine Institute, established in 1992, and currently serves as Director and Chair of the Medical Executive Committee at DxTx Pain and Spine, which he co-founded in 2020. Under his leadership, DxTx has expanded to more than 60 clinics across 10 states and delivered over one million patient visits. A 25-year Castle Connolly “Top Doctor” honoree as voted by his peers, Dr. Prunskis has dedicated his career to advancing evidence-based, minimally invasive treatments for chronic pain. Beyond clinical practice, he has played a pivotal role in shaping national policy, serving as a Presidential White House appointee to the U.S. Department of Health and Human Services Pain Management Best Practices Task Force and co-authoring its landmark 2019 Final Report. He also served three consecutive four-year terms in the Lithuanian Parliament/World Lithuanian Community Commission representing 900,000 Lithuanian Americans. For his philanthropic and professional contributions, he was bestowed the Knight of the Order of Merit by the President of Lithuania. He is Vice Chair of the American Society of Pain and Neuroscience's Artificial Intelligence (AI) Division, serves on the Advisory Board of Hippocratic AI, and is the founder of The Regenerative Stem Cell Institute. With over four decades of expertise, Dr. Prunskis bridges clinical excellence, innovation, and thoughtful public policy to expand access to ethical, effective, and technology-driven healthcare. Check out the Illinois Pain and Spine Institute's website.

Host Tammy Haddad sits down with Gary Shapiro, CEO and vice chair of the Consumer Technology Association, and Kinsey Fabrizio, CTA president, for an exclusive preview of CES 2026. Shapiro and Fabrizio discuss what Washington should expect in Las Vegas — from global attendance and robotics to Eureka Park startups, AI-driven innovation, and breakthroughs in digital health. They explain why policymakers must walk the floor in person, how discovery drives collaboration, and which technologies could shift perception and policy.

No other state in the US has Maryland's system of paying for hospital services despite its 50-year existence and the extra $2bn a year it brought. A new agreement between the state and the federal Centers for Medicare and Medicaid Services ends the preferential arrangement in 2027. Sunil Dasgupta asks Delegate Bonnie Cullison, Vice-Chair of the Maryland House Health and Government Operations Committee, and Jon Kromm, executive director of the Health Services Cost Review Commission, the state's hospital cost regulatory body, what to expect. Music by Kara Levchenko.

Robert Kaplan, Goldman Sachs vice chair and former Federal Reserve Bank of Dallas president talks about what's next for the Federal Reserve and who could be the next Fed chair.See omnystudio.com/listener for privacy information.

Prof. Ziad Nahas is a psychiatrist  and researcher who treats adult patients with mood disorders and treatment resistant depression and specializes in performing deep brain stimulation and electro-convulsive therapy. Dr. Nahas is Professor and Vice-Chair for Clinical Affairs in the Department of Psychiatry at the University of Minnesota Medical School.Today we discuss a case study of a 44 year old man with treatment resistant depression treated with PACE (Personalized Adaptive Cortical Electro-stimulation) a novel, personalised form of brain stimulation. The Case Study and video of the study patient (alias Mike) can be found here:https://www.linkedin.com/posts/ziad-nahas-67526015a_neuroscience-mentalhealthinnovation-functionalmri-activity-7360347911529910272-C08F?utm_source=share&utm_medium=member_desktop&rcm=ACoAAFjWpikBGe7Oel-gcC_2ZupvuXI-t9RkwCMInterviewed by Dr. Alex Curmi. Dr. Alex is a consultant psychiatrist and a UKCP registered psychotherapist in-training.Check out Alex on the Examined Life Podcast here:https://podcasts.apple.com/gb/podcast/dr-alex-curmi-how-should-we-prepare-for-a/id1680728280?i=1000738070553If you would like to invite Alex to speak at your organisation please email alexcurmitherapy@gmail.com with "Speaking Enquiry" in the subject line.Alex is not currently taking on new psychotherapy clients, if you are interested in working with Alex for focused behaviour change coaching , you can email - alexcurmitherapy@gmail.com with "Coaching" in the subject line.Check out The Thinking Mind Blog on Substack: https://substack.com/home/post/p-174371597Episode produced by Ellis Ballard and Alex Curmi. Give feedback here - thinkingmindpodcast@gmail.com Follow us here: Twitter @thinkingmindpod Instagram @thinkingmindpodcast

Send us a textIn this episode of WTR Small-Cap Spotlight, Stefano Valentini Chairman of DRONE VOLT  (Euronext Paris ticker symbol ALDRV), joins host Tim Gerdeman, Vice Chair, Co-Founder, and CMO of Water Tower Research, along with Dr. John Roy, WTR's Senior Equity Research Analyst. The conversation explores the strategic priorities of a drone company, focusing on its growth and go-to-market strategy in North America, specifically detailing the local production of the KOBRA drone to meet 'Made in the USA' requirements for government and critical infrastructure contracts. It also delves into the technical and business differentiators, including its LineDrone product, multi-sensor support, platform flexibility, and the scalability and margin structure of its 'Drone-as-a-Service' (DaaS) model, alongside its proactive navigation of the evolving FAA regulatory landscape for BVLOS operations.

John Brooks, 2026 Republican candidate for Colorado governor, joins Sheriff Reams to discuss the finer points of his campaign platform - with particular regard to his economic background.Home | Brooks for Colorado Governor | Official Campaign SiteRichard Holtorf, vice-chair of the Colorado Republican Party, joins Sheriff Reams on an update on the GOP's strategy going forward for races in 2026.Home - Colorado Republican Party

Carl Quintanilla, Sara Eisen, and Michael Santoli began the hour with new manufacturing data alongside a wide-ranging interview you don't want to miss: U.S. Commerce Secretary Howard Lutnick, talking everything from the jobs market to who he wants to see as the next Fed chair. Plus: Evercore's Vice Chairman Krishna Guha joined the team with his take on this morning's rough data - and what it means for a rate cut next week.  Also in focus: Microsoft shares falling on a bearish report around its AI software sales - but CNBC getting fresh news from the company pushing back. The details, this hour. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Charity Charge Show, Grayson Harris sits down with Herman Bulls, International Director and Vice Chairman at JLL, board leader across several public companies, and long time nonprofit board member. Herman shares how West Point, Army Ranger School, and decades in corporate real estate shaped his approach to leadership, relationship building, and governance.He explains how JLL supports nonprofits and public institutions with real estate strategy, why culture and preparation matter, and what effective nonprofit boards should actually be doing.About Herman Bulls Herman Bulls is an International Director and Vice Chairman at JLL, where he has spent more than 35 years helping senior executives and institutions solve complex real estate challenges. He serves as Vice Chairman of the Board at USAA, Chairman of the Board at Fluence Energy, and sits on the boards of Host Hotels and Comfort Systems USA. Herman is also Vice Chair of the Board of the American Red Cross and Vice Chair of the West Point Association of Graduates, after a distinguished career as an Army officer and finance professor at West Point. ---------------------------About Charity ChargeCharity Charge is a financial technology company serving the nonprofit sector. From the Charity Charge Nonprofit Credit Card to bookkeeping, gift card disbursements, and state compliance, we help mission-driven organizations streamline operations and stay financially strong. Learn more at charitycharge.com.

I'm joined once again by Morgan Fraser Mouchette, Vice Chair of the Matrimonial & Family Law Practice Group at Blank Rome, to talk about setting priorities in divorce.Morgan brings a wealth of experience representing clients in all aspects of family law—including divorce, custody, and high-net-worth financial matters—and her approach is as strategic as it is compassionate.In this conversation, we explore: - How to define and protect your top priorities - Choosing (and using) the right lawyer - Building your support team - Managing emotional and mental health - Supporting children and daily life - Avoiding financial pitfallsIf you're navigating divorce—or supporting someone who is—this episode is packed with grounded guidance and clarity from one of the best in the field.Connect with Morgan: https://www.blankrome.com/people/morgan-f-mouchette  

This special episode is brought to you by Zoll RespicardiaIn this episode of SleepTech Talk, we explore the newest breakthroughs in treating Central Sleep Apnea (CSA).Our guest, Timothy Morgenthaler, MD, Professor and Vice Chair, Quality and Affordability at the Mayo Clinic, and past President of the American Academy of Sleep Medicine (AASM), helps explain the updated AASM treatment guidelines and how Transvenous Phrenic Nerve Stimulation (TPNS) is now recognized as an effective therapy for CSA.We also dive deep into the Remede implant, an FDA-approved TPNS device that stimulates the phrenic nerve to help patients breathe normally during sleep. Dr. Morgenthaler breaks down how it works, which patients may benefit most, and what the AASM's new recommendations mean for clinicians and patients going forward.⭐ Main topics we cover:What's new in the AASM guidelines for Central Sleep Apnea (2025 update)Why TPNS is now an accepted therapy for CSAHow the Remede implant works and who it helpsDifferences between obstructive, central, and complex sleep apneaReal-world impact of the updated guidelines on patient careWhere TPNS fits among PAP therapy, ASV, oxygen, medications, and other treatmentsWhether you're a sleep clinician, technologist, or someone affected by sleep apnea, this episode provides a clear, practical breakdown of the latest evidence-based options for CSA.Learn more about Remede athttps://remede.zoll.com/ ABOUT SLEEPTECH TALKSleepTech Talk brings together leaders in sleep medicine, technology, and innovation to explore the tools and trends shaping the future of sleep health.Catch the show on most podcast platforms or on YouTubewww.youtube.com/@sleeptechtalk Don't forget to Like, Share, and Comment! Subscribe to SleepTech Talk for more insights into sleep apnea, CPAP therapy, and innovations shaping the future of sleep care.Whether you're a sleep professional or a healthcare innovator, this episode explores the intersection of technology, patient care, and sleep medicine.Learn more about the show at https://www.sleeptechtalk.com/thetechroomCredits:Audio/ Video: Diego R Mannikarote; Music: Pierce G MannikaroteHosts: J. Emerson Kerr, Robert Miller, Gerald George MannikaroteCopyright: ⓒ 2025 SleepTech Talk ProductionsEpisode 112The views and opinions expressed by guests on SleepTech Talk are their own and do not necessarily reflect those of the podcast hosts or SleepTech Talk as a whole. This podcast is intended for educational and informational purposes only and should not be considered medical advice. Listeners are encouraged to consult with a qualified healthcare professional for any medical concerns or questions.Sleep apnea, obstructive sleep apnea, oral sleep appliance, inspire, surgery, sleep surgery, CPAP, AI, Artificial Intelligence

Happy Thanksgiving! Here are some past interviews for you to enjoy on this holiday. Carl Cannon talks to human rights advocate Katrina Lantos Swett about threats to religious liberty here and around the world. Lantos Swett is President of the Lantos Foundation for Human Rights and Justice, and former Chair and Vice-Chair of the United States Commission on International Religious Freedom (USCIRF). Tom Bevan talks to John Tillman, the founder of MediaPedia, a new company that hopes to provide transparency when it comes to media bias. The company uses artificial intelligence to rate the ideological leaning of reporters, which it says allows it to “empower news consumers to see the bias behind the bylines of legacy news outlets.” Andrew Walworth talks to war correspondent and former New York Times Pentagon reporter Thom Shanker about singer/songwriter Warren Zevon, whose gimlet-eyed view of world politics endeared him to a generation of foreign policy practitioners and observers. Zevon, who died in 2003 from cancer, was earlier this month inducted into the Rock and Roll Hall of Fame. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

On this episode, Dr. Vladimir Manuel, Vice Chair of Clinical Affairs for the Department of Family Medicine, and Scott Jahnke, Senior Director of Operations at UCLA Health, join the podcast to discuss de-escalation of care, improving decision-making effectiveness and efficiency in healthcare, reducing admission rates, and operationalizing data to drive better outcomes.

The Inside Economics crew welcomes Alan Blinder back to the podcast. The Princeton University economics professor and former Vice Chair of the Fed offers his perspective on the outlook for artificial intelligence, the risk of a bubble in equity markets, and the potential implications of current threats to Fed independence. The team also breaks down the much-delayed September employment report.Guest: Alan Blinder – Professor of Economics and Public Affairs at Princeton UniversityGet more information on Alan Blinder's book - A Monetary and Fiscal History of the United States, 1961-2021Hosts: Mark Zandi – Chief Economist, Moody's Analytics, Cris deRitis – Deputy Chief Economist, Moody's Analytics, and Marisa DiNatale – Senior Director - Head of Global Forecasting, Moody's AnalyticsFollow Mark Zandi on 'X' and BlueSky @MarkZandi, Cris deRitis on LinkedIn, and Marisa DiNatale on LinkedIn Questions or Comments, please email us at helpeconomy@moodys.com. We would love to hear from you. To stay informed and follow the insights of Moody's Analytics economists, visit Economic View. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.